Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nuwellis Inc (NUWE)

Nuwellis Inc (NUWE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,401
  • Shares Outstanding, K 6,801
  • Annual Sales, $ 8,860 K
  • Annual Income, $ -20,210 K
  • 60-Month Beta 0.31
  • Price/Sales 0.10
  • Price/Cash Flow N/A
  • Price/Book 0.29
Trade NUWE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.79
  • Most Recent Earnings $-2.24 on 03/05/24
  • Latest Earnings Date 05/07/24 [BMO]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.09
  • Growth Rate Est. (year over year) +19,726.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1250 +74.40%
on 05/01/24
0.4099 -46.82%
on 04/09/24
-0.1670 (-43.38%)
since 04/03/24
3-Month
0.1250 +74.40%
on 05/01/24
0.7888 -72.36%
on 02/20/24
-0.2620 (-54.58%)
since 02/02/24
52-Week
0.1250 +74.40%
on 05/01/24
4.5900 -95.25%
on 05/08/23
-4.1820 (-95.05%)
since 05/03/23

Most Recent Stories

More News
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END

SILO : 1.8000 (-2.70%)
BXRX : 0.0218 (+7.39%)
HOTH : 1.1875 (-3.38%)
KALA : 6.83 (+1.11%)
NUWE : 0.1990 (-3.40%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...

SILO : 1.8000 (-2.70%)
BXRX : 0.0218 (+7.39%)
HOTH : 1.1875 (-3.38%)
KALA : 6.83 (+1.11%)
NUWE : 0.1990 (-3.40%)
Nuwellis (NASDAQ: NUWE) Reports Clinical Data Showing 100% Survival Rate Using Ultrafiltration in High-Risk CABG Patients

Nuwellis, Inc. (NASDAQ: NUWE) is engaged as a medical device company, which is focused on the development and commercialization of

NUWE : 0.1990 (-3.40%)
Nuwellis, Inc. Announces Second Quarter 2022 Financial Results

MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022,...

NUWE : 0.1990 (-3.40%)
Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

The Finkelstein-Schoenfeld Method of Win Ratios Analysis Provides New Insights Into Superiority of Ultrafiltration over Diuretics in Treating Fluid...

NUWE : 0.1990 (-3.40%)
Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022

MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be...

NUWE : 0.1990 (-3.40%)
Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for...

NUWE : 0.1990 (-3.40%)
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload...

NUWE : 0.1990 (-3.40%)
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

Pediatric Segment Growth Continues at 36% CAGR...

NUWE : 0.1990 (-3.40%)
Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

MINNEAPOLIS, May 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company’s 2022 Annual Meeting of Stockholders, on...

NUWE : 0.1990 (-3.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuwellis Inc. is a medical device company. It is focused on developing, manufacturing and commercializing the Aquadex SmartFlow(R) System for ultrafiltration therapy. Nuwellis Inc., formerly known as CHF Solutions, is headquartered in Minneapolis, Minn.

See More

Key Turning Points

3rd Resistance Point 0.3980
2nd Resistance Point 0.3312
1st Resistance Point 0.2686
Last Price 0.1990
1st Support Level 0.1392
2nd Support Level 0.0724
3rd Support Level 0.0098

See More

52-Week High 4.5900
Fibonacci 61.8% 2.8844
Fibonacci 50% 2.3575
Fibonacci 38.2% 1.8306
Last Price 0.1990
52-Week Low 0.1250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar